Vanda Pharmaceuticals Inc.
VNDA
$4.42
$0.1052.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.09% | -5.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.09% | -5.91% | |||
| Cost of Revenue | -22.29% | 35.95% | |||
| Gross Profit | 7.17% | -8.05% | |||
| SG&A Expenses | 29.02% | 27.50% | |||
| Depreciation & Amortization | -0.06% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.03% | 43.50% | |||
| Operating Income | 6.15% | -299.14% | |||
| Income Before Tax | 6.64% | -475.16% | |||
| Income Tax Expenses | 2.46% | -396.78% | |||
| Earnings from Continuing Operations | 7.75% | -500.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.75% | -500.45% | |||
| EBIT | 6.15% | -299.14% | |||
| EBITDA | 6.56% | -370.08% | |||
| EPS Basic | 8.47% | -498.46% | |||
| Normalized Basic EPS | 7.37% | -175.93% | |||
| EPS Diluted | 8.47% | -459.89% | |||
| Normalized Diluted EPS | 7.37% | -175.93% | |||
| Average Basic Shares Outstanding | 0.80% | 0.38% | |||
| Average Diluted Shares Outstanding | 0.80% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||